Jones G L, Spencer L, Lord R, Mollard R, Pye D, Saul A
Queensland Institute of Medical Research, Herston, Australia.
Immunol Lett. 1990 Jul;24(4):253-60. doi: 10.1016/0165-2478(90)90008-e.
Peptides P2122 (CKNNNSTNSGI) and P513 (CSQRSTNSAST) containing an epitope of a malarial surface antigen (MSA2) recognised by inhibitory monoclonal antibodies were conjugated to diphtheria toxoid (DT) protein and formulated with various gel-based and water in oil emulsion adjuvants in vaccine trials in mice and rabbits. The P2122-DT construct was effective in raising antibodies reactive with both the immunising peptide and the native antigen. Effective adjuvanticity as measured by the titre of the anti-peptide or anti-protein response in mice varied in the order: Algammulin, Montanide ISA 50 greater than or equal to Freund's adjuvant, Montanide ISA 708, 721, 70 much greater than alum, Squalene Arlacel greater than SAF-1. A similar order of adjuvant efficacy: Freund's greater than alum greater than Squalene Arlacel greater than SAF-1, was observed in rabbits.
含有被抑制性单克隆抗体识别的疟原虫表面抗原（MSA2）表位的肽P2122（CKNNNSTNSGI）和P513（CSQRSTNSAST）与白喉类毒素（DT）蛋白偶联，并在小鼠和兔子的疫苗试验中与各种基于凝胶的和油包水乳液佐剂一起配制。P2122-DT构建体在产生与免疫肽和天然抗原都反应的抗体方面是有效的。通过小鼠中抗肽或抗蛋白反应的滴度测量的有效佐剂活性按以下顺序变化：Algammulin、Montanide ISA 50大于或等于弗氏佐剂、Montanide ISA 708、721、70远大于明矾、角鲨烯Arlacel大于SAF-1。在兔子中观察到类似的佐剂效力顺序：弗氏佐剂大于明矾大于角鲨烯Arlacel大于SAF-1。
